A kinetic model predicts SpCas9 activity, improves off-target classification, and reveals the physical basis of targeting fidelity
Behrouz Eslami-Mossallam (TU Delft - BN/Martin Depken Lab, Kavli institute of nanoscience Delft)
Misha Klein (TU Delft - BN/Martin Depken Lab, Kavli institute of nanoscience Delft)
Constantijn V.D. Smagt (Kavli institute of nanoscience Delft)
Koen V.D. Sanden (Kavli institute of nanoscience Delft)
Stephen K. Jones (The University of Texas at Austin)
John A. Hawkins (The University of Texas at Austin)
Ilya J. Finkelstein (The University of Texas at Austin)
Martin Depken (TU Delft - BN/Bionanoscience, Kavli institute of nanoscience Delft)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The S. pyogenes (Sp) Cas9 endonuclease is an important gene-editing tool. SpCas9 is directed to target sites based on complementarity to a complexed single-guide RNA (sgRNA). However, SpCas9-sgRNA also binds and cleaves genomic off-targets with only partial complementarity. To date, we lack the ability to predict cleavage and binding activity quantitatively, and rely on binary classification schemes to identify strong off-targets. We report a quantitative kinetic model that captures the SpCas9-mediated strand-replacement reaction in free-energy terms. The model predicts binding and cleavage activity as a function of time, target, and experimental conditions. Trained and validated on high-throughput bulk-biochemical data, our model predicts the intermediate R-loop state recently observed in single-molecule experiments, as well as the associated conversion rates. Finally, we show that our quantitative activity predictor can be reduced to a binary off-target classifier that outperforms the established state-of-the-art. Our approach is extensible, and can characterize any CRISPR-Cas nuclease – benchmarking natural and future high-fidelity variants against SpCas9; elucidating determinants of CRISPR fidelity; and revealing pathways to increased specificity and efficiency in engineered systems.